8 Best Life Sciences Penny Stocks to Buy
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate.
Nautilus Biotechnology Inc. (NAUT)
Market is closed
Sector: Healthcare
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Cercano Management Chris Orndorff | 7,172,985 | $27,831,182 | 1.2% | |
| 2. | Hudson Bay Capital Management Sander Gerber | 29,594 | $114,825 | +56% | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.61 | 25,000 | $65,237.50 | 10,366,721 | 2026-03-04 | Filing | |
| $1.49 | 4,000 | $5,960.00 | 4,000 | 2025-11-06 | Filing | |
| $0.68 | 83,500 | $57,030.50 | 10,341,721 | 2025-09-08 | Filing | |
| $0.67 | 116,500 | $78,544.30 | 10,258,221 | 2025-09-05 | Filing | |
| $0.64 | 20,000 | $12,858.00 | 74,140 | 2025-09-04 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $2.87 | 47,031 | $134,743.82 | 0 | 2024-09-23 | Filing | |
| $2.85 | 35,000 | $99,869.00 | 0 | 2024-09-17 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 2,545,597 | $9,876,916 | 0% | |
| 2. | 2,329,784 | $9,039,562 | 0.08% | |
| 3. | 1,457,055 | $5,653,373 | 0.21% | |
| 4. | 329,123 | $1,273,767 | 0% | |
| 5. | 305,526 | $1,185,441 | 0% |
News See All
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 2025 Earnings Conference Call.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2025 Earnings Call Transcript
Operator: Good day and thank you for standing by. Welcome to the Nautilus Biotechnology Third Quarter 2025 Earnings Conference Call.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2025 Earnings Call Transcript
Operator: Good day, ladies and gentlemen, and thank you for standing by. Welcome to the Nautilus Biotechnology Second Quarter 2025 Earnings Conference Call.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2025 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nautilus First Quarter 2025 Earnings Conference Call. At this time, all participants are in listen-only mode.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2024 Earnings Call Transcript
Operator: Good day, and thank you for standing by. Welcome to the Nautilus Fourth Quarter and Full Year 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q3 2024 Earnings Call Transcript
Operator: Good day everyone, and thank you for standing by and welcome to Nautilus Third Quarter 2024 Earnings Conference Call. At this time, all participants are in a listen-only mode.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q2 2024 Earnings Call Transcript
Operator: Good day and thank you for standing by and welcome to Nautilus Q2 2024 Earnings Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q1 2024 Earnings Call Transcript
Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $-0.00015, expectations were $-0.16.
Nautilus Biotechnology, Inc. (NASDAQ:NAUT) Q4 2023 Earnings Call Transcript
Nautilus Biotechnology, Inc. beats earnings expectations. Reported EPS is $0.14, expectations were $-0.16.
Hedge Fund Resource Center